N. Vrindavanam

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy.

K. Kelly, G. Weiss, A. Heydebreck, 2015 .

Fenfluramine challenge in anxious children

G. Sethuraman, F. Sallee, N. Vrindavanam, 2000, Human psychopharmacology.

Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial

H. Wakelee, T. Lynch, V. Miller, 2008 .

Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial.

G. Sethuraman, F. Sallee, S. Carson, 1997, The American journal of psychiatry.

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

L. Sequist, J. Nemunaitis, E. Juhász, 2014, Journal of Immunotherapy for Cancer.

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib

H. Wakelee, T. Lynch, V. Miller, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome

G. Sethuraman, F. Sallee, N. Vrindavanam, 1996, Biological Psychiatry.

Dramatic response to single‐agent rituximab in a patient with intravascular lymphoma

S. Suster, F. Awan, M. Hamadani, 2007, American journal of hematology.

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2‐Positive Locally Recurrent or Metastatic Breast Cancer

H. Wildiers, A. Stopeck, G. Jerusalem, 2019, Clinical breast cancer.

Parenteral clomipramine challenge in depressed adolescents: mood and neuroendocrine response

G. Sethuraman, F. Sallee, S. Carson, 1998, Biological Psychiatry.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib

H. Wakelee, V. Miller, M. Pietanza, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.